Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

Urology

Volumn 60, Issue 6, 2002, Pages 1040-1044

  Vaughan, D ^a,b,c,d,e,f   Imperato McGinley, J ^a,b,c,d,e,f   McConnell, J ^a,b,c,d,e,f   Matsumoto, A M ^a,b,c,d,e,f   Bracken, B ^a,b,c,d,e,f   Roy, J ^a,b,c,d,e,f   Sullivan, M ^a,b,c,d,e,f   Pappas, F ^a,b,c,d,e,f   Cook, T ^a,b,c,d,e,f   Daurio, C ^a,b,c,d,e,f   Meehan, A ^a,b,c,d,e,f   Stoner, E ^a,b,c,d,e,f   Waldstreicher, Joanne ^a,b,c,d,e,f  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Mercy Research Clinic   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ECHOGRAPHY; EJACULATION DISORDER; HUMAN; IMPOTENCE; LIBIDO DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE FLOW RATE;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; URINATION;

EID: 0036900783     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01971-4     Document Type: Article

References (17)

1. McConnell J.D. The pathophysiology of benign prostatic hyperplasia. J Androl. 12:1991;356-363.
2. Stoner E. The clinical effects of a 5α-reductase inhibitor, finasteride on benign prostatic hyperplasia. J Urol. 147:1992;1298-1302.
3. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
4. Stoner E. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
5. Andersen J.T., Ekman P., Wolf H., et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A 2-year placebo-controlled study. Urology. 46:1995;631-637.
6. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J. 155:1996;1251-1259.
7. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study. Urology. 51:1998;677-686.
8. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
9. Andersen J.T., Nickel J.C., Marshall V.R., et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:1997;839-845.
10. Marberger M.J., Andersen J.T., Nickel J.C., et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention combined experience from three large multinational placebo-controlled trials. Eur Urol. 38:2000;563-568.
11. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl. 12:1991;372-375.
12. Moore E., Bracken B., Bremner W., et al. Proscar five-year experience. Eur Urol. 28:1995;304-309.
13. Boyarsky S., Jones G., Paulson D.F., et al. A new look at bladder neck obstruction by the Food and Drug Administration regulators guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Gen-Urin Surg. 68:1977;29-32.
14. Bolognese J.A., Kozloff R.C., Kunitz S.C., et al. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate. 21:1992;247-254.
15. Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years follow-up of the Scandinavian Open-Extension Study. Eur Urol. 33:1998;312-317.
16. Hudson P.B., Boake R., Trachtenberg J., et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology. 53:1999;690-695.
17. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology. 45:1995;406-413.